174 related articles for article (PubMed ID: 36506043)
1. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.
Reinert T; Cascelli F; de Resende CAA; Gonçalves AC; Godo VSP; Barrios CH
Front Endocrinol (Lausanne); 2022; 13():1015388. PubMed ID: 36506043
[TBL] [Abstract][Full Text] [Related]
2. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
3. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
6. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype.
Deyarmin B; Kane JL; Valente AL; van Laar R; Gallagher C; Shriver CD; Ellsworth RE
Ann Surg Oncol; 2013 Jan; 20(1):87-93. PubMed ID: 22875649
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
8. Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.
Dixon JM; Cameron DA; Arthur LM; Axelrod DM; Renshaw L; Thomas JS; Turnbull A; Young O; Loman CA; Jakubowski D; Baehner FL; Singh B
Adv Ther; 2019 Apr; 36(4):828-841. PubMed ID: 30859501
[TBL] [Abstract][Full Text] [Related]
9. Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.
Li Q; Eklund AC; Juul N; Haibe-Kains B; Workman CT; Richardson AL; Szallasi Z; Swanton C
PLoS One; 2010 Dec; 5(12):e15031. PubMed ID: 21152022
[TBL] [Abstract][Full Text] [Related]
10. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
Xia S; Lin Q
Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
Harvey JM; Clark GM; Osborne CK; Allred DC
J Clin Oncol; 1999 May; 17(5):1474-81. PubMed ID: 10334533
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-low breast cancer: Biology chaos and treatment paradox.
Yu KD; Cai YW; Wu SY; Shui RH; Shao ZM
Cancer Commun (Lond); 2021 Oct; 41(10):968-980. PubMed ID: 34251757
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
Iwamoto T; Booser D; Valero V; Murray JL; Koenig K; Esteva FJ; Ueno NT; Zhang J; Shi W; Qi Y; Matsuoka J; Yang EJ; Hortobagyi GN; Hatzis C; Symmans WF; Pusztai L
J Clin Oncol; 2012 Mar; 30(7):729-34. PubMed ID: 22291085
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.
Brechbuhl HM; Finlay-Schultz J; Yamamoto TM; Gillen AE; Cittelly DM; Tan AC; Sams SB; Pillai MM; Elias AD; Robinson WA; Sartorius CA; Kabos P
Clin Cancer Res; 2017 Apr; 23(7):1710-1721. PubMed ID: 27702820
[No Abstract] [Full Text] [Related]
17. Characterization of estrogen receptor-low-positive breast cancer.
Fei F; Siegal GP; Wei S
Breast Cancer Res Treat; 2021 Jul; 188(1):225-235. PubMed ID: 33694051
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
Alles MC; Gardiner-Garden M; Nott DJ; Wang Y; Foekens JA; Sutherland RL; Musgrove EA; Ormandy CJ
PLoS One; 2009; 4(3):e4710. PubMed ID: 19270750
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
